European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Brilique, ticagrelor, Date of authorisation: 03/12/2010, Revision: 25, Status: Authorised

Submitted by Anonymous (not verified) on 18 August 2026 - 14:35

Human medicines European public assessment report (EPAR): Brilique, ticagrelor, Date of authorisation: 03/12/2010, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Tuznue, trastuzumab, Date of authorisation: 19/09/2024, Revision: 5, Status: Authorised

Submitted by Anonymous (not verified) on 18 August 2026 - 13:47

Human medicines European public assessment report (EPAR): Tuznue, trastuzumab, Date of authorisation: 19/09/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Amgevita, adalimumab, Date of authorisation: 21/03/2017, Revision: 16, Status: Authorised

Submitted by Anonymous (not verified) on 18 August 2026 - 13:42

Human medicines European public assessment report (EPAR): Amgevita, adalimumab, Date of authorisation: 21/03/2017, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Yaxwer, denosumab, Date of authorisation: 23/06/2025, Revision: 1, Status: Authorised

Submitted by Anonymous (not verified) on 18 August 2026 - 13:38

Human medicines European public assessment report (EPAR): Yaxwer, denosumab, Date of authorisation: 23/06/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Dupixent, dupilumab, Date of authorisation: 26/09/2017, Revision: 49, Status: Authorised

Submitted by Anonymous (not verified) on 18 August 2026 - 12:57

Human medicines European public assessment report (EPAR): Dupixent, dupilumab, Date of authorisation: 26/09/2017, Revision: 49, Status: Authorised

Human medicines European public assessment report (EPAR): Conexxence, denosumab, Date of authorisation: 18/07/2025, Revision: 2, Status: Authorised

Submitted by Anonymous (not verified) on 18 August 2026 - 12:37

Human medicines European public assessment report (EPAR): Conexxence, denosumab, Date of authorisation: 18/07/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Temodal, temozolomide, Date of authorisation: 26/01/1999, Revision: 41, Status: Authorised

Submitted by Anonymous (not verified) on 18 August 2026 - 10:05

Human medicines European public assessment report (EPAR): Temodal, temozolomide, Date of authorisation: 26/01/1999, Revision: 41, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More